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Introduction
In acute ST-segment elevation myocardial infarction
(STEMI), rapid restoration of epicardial coronary blood
flow and myocardial perfusion limits infarct size and
improves survival. Primary percutaneous coronary inter-
vention (PCI) is superior to systemic fibrinolysis when
instantly performed by experienced operators. The "Her-
zinfarktverbund Essen" (HIVE) is an urban STEMI net-
work supporting direct patient transfer for primary PCI to
4 PCI centers covering a city area of 600.000 inhabitants.
Integrated health care is an optional part of the HIVE
allowing for reimbursement of medical innovations such
as the evaluation of infarct size and the presence and
extent of microvascular obstruction by contrast-enhanced
CMR.
Objectives
Aim of the study was to assess the prognostic impact of
contrast-enhanced CMR in a patient cohort of a regional
STEMI network.
Methods
Within the first year (09/04 to 08/05) of the HIVE registry
489 patients with acute myocardial infarction were treated
in the 4 primary PCI centers. In one of the centers, includ-
ing 143 patients, early CMR imaging using a standardized
MR protocol for infarct quantification was performed
whenever possible. Patients with hemodynamic instabil-
ity, emergency CABG, resuscitation or death prior to CMR,
claustrophobia, and other general contraindications to
MRI had to excluded leaving 67 patients (54 male; mean
age, 61 ± 12 years) for the final evaluation.
CMR was performed 4.5 ± 2.5 days after admission on a
1.5 Tesla MR Scanner (Avanto, Siemens Medical Solu-
tions, Erlangen, Germany) including steady-state free pre-
cession (SSFP) cine imaging for LV function and single
shot inversion-recovery SSFP imaging for delayed
enhancement (DE) and no-reflow (NR) evaluation fol-
lowing injection of 0.2 mmol/kg BW gadodiamide
(Omniscan, GE Healthcare Buchler, Munich, Germany).
LV volumes and myocardial mass were calculated from
planimetry of contiguous short axis slices and summation
of discs. NR volumes were calculated from single-shot
short axis stacks taken within the first minute following
gadodiamide infusion by manual planimetry and sum-
mation of discs. DE volumes were calculated from the
inversion-recovery SSFP images taken at least 10 minutes
after contrast administration.
1-year-follow-up data (telephone interview) for major
adverse cardiac events (MACE: cardiac death, myocardial
infarction, and re-hospitalization for congestive heart fail-
ure, angina pectoris, or revascularization) were available
from all patients.
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DE as a measure of infarct size was 9 ± 7% (0 to 33%) of
LV mass, and mean volume of microvascular obstruction
was 2 ± 3% (range 0 to 17%). Microvascular obstruction
was present in 61% of patients.
Infarct localization was anterior in 37 patients (infarct
size, 10 ± 9% of LV mass; microvascular obstruction, 3 ±
4% of LV mass; LVEF, 43 ± 13%; LVEDV, 143 ± 37 ml;
LVESV, 80 ± 27 ml) with NR in 22 of 37 (60%), and infe-
rior in 30 cases (DE, 8 ± 6%, NR, 1 ± 2%; LVEF, 52 ± 15%;
LVEDV, 146 ± 52 ml; LVESV, 75 ± 55 ml) with NR in 19
of 30 (63%) patients.
16 MACE (1 cardiac death, 1 myocardial infarction, and
14 re-hospitalizations for congestive heart failure or
unstable angina pectoris with PCI in 6 cases) occurred
within the follow-up period of 430 ± 63 days.
Patients with MACE had larger infarcts (14 ± 10% vs. 8 ±
6% DE), lower LVEF (44 ± 17% vs. 48 ± 14%) and larger
NR (3 ± 5% vs 2 ± 3%). Using a stepwise logistic regres-
sion model, only NR > 0.5% of LV mass was independ-
ently related to outcome (OR = 3.9, CI 1.1–13.9).
Conclusion
No-reflow as a correlate of microvascular obstruction
remains independently related to prognosis in patients
with acute myocardial infarction treated by PCI.Page 2 of 3
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Kaplan-Meier Curve for Event-free SurvivalFigure 1
Kaplan-Meier Curve for Event-free Survival.
